000			01406na a2200241 4500
003			H12O
005			20180417112304.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aGómez Martín, Carlos _91064 _eOncología Médica
245	0	0	_aIncidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. _h[artículo]
260			_bClinical & translational oncology, _c2012
300			_a14(9):689-97.
500			_aFormato Vancouver: Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012 Sep;14(9):689-97.
501			_aPMID: 22855151
504			_aContiene 27 referencias
520			_aHand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
710			_9303 _aServicio de Oncología Médica
773	0		_g
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/4/pc4436.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c4436 _d4436